Andrzej Habior

Andrzej Habior

Auto-generated profile, based on publicly available information

Andrzej Habior

Clinic of Polish Gastroenterology Foundation, 02-653 Warsaw, Poland

Research Focus & Metrics

Academic Career Length

49Years (1978-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2005 in Journal of Hepatology
Verified
Journal Article
Closed access
AMAlexander R Moschen
Alexander R Moschen
AKArthur Kaser
Arthur Kaser
SSSylvia Stadlmann
Sylvia Stadlmann
GMGunda Millonig
Gunda Millonig
SKSusanne Kaser
Susanne Kaser
HTHerbert Tilg
Herbert Tilg

1 October 1999 in Hepatology
Verified
Journal Article
Open access
PDF file
PKPiotr Krzeski
Piotr Krzeski
WZWlodzimierz Zych
Wlodzimierz Zych
EKEwa Kraszewska
Ewa Kraszewska
BMBohdan Milewski
Bohdan Milewski
EBEugeniusz Butruk
Eugeniusz Butruk
AHAndrzej Habior
Andrzej Habior
From the many prognostic models for primary biliary cirrhosis (PBC) patients based on Cox's regression analysis, the Mayo model has gained the most popularity and was successfully validated in some centers. The aim of our study was to validate the Mayo survival model for Polish PBC patients and, in case of its inapplicability, to select prognostic variables and to create time-fixed and time-dependent survival models for the patients. We used database information on patients from 6 medical centers in Poland, fulfilling clinical, serological, and/or pathological criteria of PBC. The Mayo model was validated using data from 116 PBC patients. The time-fixed and time-dependent models were created using data on clinical and biochemical variables used in the Mayo model from 162 and 208 patients, respectively. The Mayo model validation was performed graphically and by one-sample log-rank tests after dividing the study sample into 3 groups of high, medium, and low risk. The survival analysis was performed using Cox's proportional hazards regression method on clinical and biochemical variables used in the Mayo model. Treatment with ursodeoxycholic acid (UDCA) was included in the time-dependent analysis. Validation showed that the Mayo model overestimated death risk in Polish PBC patients. Of the variables used in the Mayo model, serum bilirubin concentration appeared to be the only variable of prognostic importance. The analysis shows that serum bilirubin concentration holds most of the prognostic information for our PBC patients irrespective of prior treatment with UDCA.

21 August 2008 in BMC Medical Genetics
Verified
Journal Article
Open access
PDF file
PGPawel Gaj
Pawel Gaj
AHAndrzej Habior
Andrzej Habior
MMMichal Mikula
Michal Mikula
JOJerzy Ostrowski
Jerzy Ostrowski
Numerous papers have addressed the association of mutations and polymorphisms of susceptibility genes with autoimmune inflammatory disorders. We investigated whether polymorphisms that confer susceptibility to Crohn's disease could be classified also as predisposing factors for the development of primary sclerosing cholangitis and primary biliary cirrhosis in Polish patients.

1 November 2017 in Journal of Hepatology
Verified
Journal Article
Open access
MKMaria Kulecka
Maria Kulecka
AWAldona Wierzbicka-Rucińska
Aldona Wierzbicka-Rucińska
APAgnieszka Paziewska
Agnieszka Paziewska
MMMichal Mikula
Michal Mikula
AHAndrzej Habior
Andrzej Habior
JOJerzy Ostrowski
Jerzy Ostrowski
Macro-aspartate aminotransferase (macro-AST) manifests as a persistent elevation of AST levels, because of association of the protein with immunoglobulins in the circulation. Macro-AST is a rare, benign condition without a previously confirmed genetic basis. Whole exome sequencing (WES)-based screening was performed on 32 participants with suspected familial macro-AST, while validation of variants was performed on an extended cohort of 92 probands and 1,644 healthy controls using Taqman genotyping. A missense variant (p.Gln208Glu, rs374966349) in glutamate oxaloacetate transaminase 1 (GOT1) was found, as a putative causal variant predisposing to familial macro-AST. The GOT1 p.Gln208Glu mutation was detected in 50 (54.3%) of 92 probands from 20 of 29 (69%) families, while its prevalence in healthy controls was only 0.18%. In silico analysis demonstrated that the amino acid at this position is not conserved among different species and that, functionally, a negatively charged glutamate on the GOT1 surface could strongly anchor serum immunoglobulins. Our data highlight that testing for the p.Gln208Glu genetic variant may be useful in diagnosis of macro-AST. Higher than normal levels of aspartate aminotransferase (AST) in the bloodstream may be a sign of a health problem. Individuals with macro-AST have elevated blood AST levels, without ongoing disease and often undergo unnecessary medical tests before the diagnosis of macro-AST is established. We found a genetic variant in the GOT1 gene associated with macro-AST. Genetic testing for this variant may aid diagnosis of macro-AST.

1 July 2002 in European Journal of Gastroenterology & Hepatology
Verified
Journal Article
Closed access
AHAndrzej Habior
Andrzej Habior
TRTomasz Rawa
Tomasz Rawa
JOJanina Oruulowska
Janina Oruulowska
MSMonika Sankowska
Monika Sankowska
ALAleksandra Lewartowska
Aleksandra Lewartowska
EBEugeniusz Butruk
Eugeniusz Butruk
Primary sclerosing cholangitis is a rare, cholestatic liver disease, most commonly affecting young men. The association of primary sclerosing cholangitis with other autoimmune disorders, although rare, indicates a genetic predisposition for this disease. We describe, for the first time, the association of primary sclerosing cholangitis, ulcerative colitis and coeliac disease in two sisters. Ulcerative colitis was mild and preceded liver disease in both patients. There were no symptoms of coeliac disease, and its silent form was diagnosed on the basis of serological tests. Both patients carried HLA molecules DR3 and DQ2. Although HLA DR4 was not found, there was a rapid progression of liver disease to cirrhosis and cholangiocarcinoma in one patient. The familial occurrence of primary sclerosing cholangitis, ulcerative colitis and coeliac disease supports the hypothesis of genetic predisposition for these diseases.

1 January 2012 in Polish Journal of Surgery
Verified
Journal Article
Open access
PDF file
MKMarek Krawczyk
Marek Krawczyk
MGMichał Grąt
Michał Grąt
KBKrzysztof Barski
Krzysztof Barski
JLJoanna Ligocka
Joanna Ligocka
AAArkadiusz Antczak
Arkadiusz Antczak
JSJerzy Szczerbań
Jerzy Szczerbań
The aim of the study was to analyze indications and results of the first one thousand liver transplantations at Chair and Clinic of General, Transplantation and Liver Surgery, Medical University of Warsaw. Material and methods. Data from 1000 transplantations (944 patients) performed at Chair and Clinic of General, Transplantation and Liver Surgery between 1994 and 2011 were analyzed retrospectively. These included 943 first transplantations and 55 retransplantations and 2 re-retransplantations. Frequency of particular indications for first transplantation and retransplantations was established. Perioperative mortality was defined as death within 30 days after the transplantation. Kaplan-Meier survival analysis was used to estimate 5-year patient and graft survival. Results. The most common indications for first transplantation included: liver failure caused by hepatitis C infection (27.8%) and hepatitis B infection (18%) and alcoholic liver disease (17.7%). Early (< 6 months) and late (> 6 months) retransplantations were dominated by hepatic artery thrombosis (54.3%) and recurrence of the underlying disease (45%). Perioperative mortality rate was 8.9% for first transplantations and 34.5% for retransplantations. Five-year patient and graft survival rate was 74.3% and 71%, respectively, after first transplantations and 54.7% and 52.9%, respectively, after retransplantations. Conclusions. Development of liver transplantation program provided more than 1000 transplantations and excellent long-term results. Liver failure caused by hepatitis C and B infections remains the most common cause of liver transplantation and structure of other indications is consistent with European data.